Prospective trial showed levofloxacin is more effective than pranoprofen in bacterial conjunctivitis, suggesting a preferred treatment option.
This study compared the efficacy and safety of levofloxacin eye drops and pranoprofen gel in treating bacterial conjunctivitis via a prospective randomized controlled design. A total of 200 patients with bacterial conjunctivitis were included, randomly divided into two groups (100 cases each) for 14-day corresponding drug treatment. Symptom improvement, bacterial clearance and adverse reactions were observed. Results showed that on treatment days 1 and 3, the levofloxacin group had significantly lower scores in conjunctival congestion (1.9±0.4 vs 2.1±0.5; 1.5±0.3 vs 1.7±0.4) and secretions (2.1±0.5 vs 2.3±0.6; 1.7±0.4 vs 1.9±0.5) than the pranoprofen group (all P<0.05). The bacterial clearance rate of the levofloxacin group was 85% (85/100), significantly higher than the pranoprofen group’s 70% (70/100) (?²=5.32, P<0.05). The total effective rate of the levofloxacin group was 90% (90/100), significantly higher than the pranoprofen group’s 80% (80/100) (?²=3.92, P<0.05). For safety, the adverse reaction incidence was 15% (15/100) in the levofloxacin group and 13% (13/100) in the pranoprofen group, with no significant difference (?²=0.258, P=0.612). This study indicates levofloxacin eye drops have efficacy advantages, and the two are comparable in safety, providing a valuable medication reference for clinical treatment of bacterial conjunctivitis
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: